Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 1.25
XNPT's Cash to Debt is ranked lower than
78% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. XNPT: 1.25 )
Ranked among companies with meaningful Cash to Debt only.
XNPT' s Cash to Debt Range Over the Past 10 Years
Min: 1.25  Med: 9999.50 Max: No Debt
Current: 1.25
Equity to Asset 0.12
XNPT's Equity to Asset is ranked lower than
91% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. XNPT: 0.12 )
Ranked among companies with meaningful Equity to Asset only.
XNPT' s Equity to Asset Range Over the Past 10 Years
Min: -1.61  Med: 0.70 Max: 0.82
Current: 0.12
-1.61
0.82
F-Score: 2
Z-Score: -4.89
M-Score: -3.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -192.47
XNPT's Operating margin (%) is ranked lower than
61% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. XNPT: -192.47 )
Ranked among companies with meaningful Operating margin (%) only.
XNPT' s Operating margin (%) Range Over the Past 10 Years
Min: -2892.15  Med: -176.68 Max: 18.25
Current: -192.47
-2892.15
18.25
Net-margin (%) -199.98
XNPT's Net-margin (%) is ranked lower than
62% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. XNPT: -199.98 )
Ranked among companies with meaningful Net-margin (%) only.
XNPT' s Net-margin (%) Range Over the Past 10 Years
Min: -2864.5  Med: -171.24 Max: 24.77
Current: -199.98
-2864.5
24.77
ROE (%) -154.50
XNPT's ROE (%) is ranked lower than
89% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. XNPT: -154.50 )
Ranked among companies with meaningful ROE (%) only.
XNPT' s ROE (%) Range Over the Past 10 Years
Min: -147.73  Med: -60.68 Max: 27
Current: -154.5
-147.73
27
ROA (%) -47.25
XNPT's ROA (%) is ranked lower than
68% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. XNPT: -47.25 )
Ranked among companies with meaningful ROA (%) only.
XNPT' s ROA (%) Range Over the Past 10 Years
Min: -72.3  Med: -44.62 Max: 18.7
Current: -47.25
-72.3
18.7
ROC (Joel Greenblatt) (%) -3657.93
XNPT's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. XNPT: -3657.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XNPT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3735.36  Med: -861.15 Max: 561.29
Current: -3657.93
-3735.36
561.29
Revenue Growth (3Y)(%) 5.90
XNPT's Revenue Growth (3Y)(%) is ranked higher than
51% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. XNPT: 5.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XNPT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -72.3  Med: -12.05 Max: 126.5
Current: 5.9
-72.3
126.5
EBITDA Growth (3Y)(%) 19.80
XNPT's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. XNPT: 19.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XNPT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.3  Med: -13.60 Max: 19.8
Current: 19.8
-54.3
19.8
EPS Growth (3Y)(%) 18.60
XNPT's EPS Growth (3Y)(%) is ranked higher than
75% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. XNPT: 18.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XNPT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.3  Med: -12.30 Max: 18.6
Current: 18.6
-52.3
18.6
» XNPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

XNPT Guru Trades in Q1 2015

Charles Brandes 19,700 sh (unchged)
PRIMECAP Management 91,000 sh (unchged)
Paul Tudor Jones 17,570 sh (-5.28%)
» More
Q2 2015

XNPT Guru Trades in Q2 2015

Jim Simons 173,936 sh (New)
PRIMECAP Management 91,000 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes Sold Out
» More
Q3 2015

XNPT Guru Trades in Q3 2015

Paul Tudor Jones 109,200 sh (New)
PRIMECAP Management 91,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

XNPT Guru Trades in Q4 2015

Chuck Royce 690,200 sh (New)
PRIMECAP Management 91,000 sh (unchged)
Paul Tudor Jones 31,200 sh (-71.43%)
» More
» Details

Insider Trades

Latest Guru Trades with XNPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.86
XNPT's P/B is ranked lower than
88% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. XNPT: 12.86 )
Ranked among companies with meaningful P/B only.
XNPT' s P/B Range Over the Past 10 Years
Min: 1.71  Med: 4.29 Max: 18.5
Current: 12.86
1.71
18.5
P/S 6.33
XNPT's P/S is ranked higher than
64% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. XNPT: 6.33 )
Ranked among companies with meaningful P/S only.
XNPT' s P/S Range Over the Past 10 Years
Min: 2.64  Med: 13.62 Max: 105.87
Current: 6.33
2.64
105.87
Current Ratio 8.01
XNPT's Current Ratio is ranked higher than
68% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. XNPT: 8.01 )
Ranked among companies with meaningful Current Ratio only.
XNPT' s Current Ratio Range Over the Past 10 Years
Min: 3.41  Med: 6.43 Max: 11.26
Current: 8.01
3.41
11.26
Quick Ratio 7.91
XNPT's Quick Ratio is ranked higher than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. XNPT: 7.91 )
Ranked among companies with meaningful Quick Ratio only.
XNPT' s Quick Ratio Range Over the Past 10 Years
Min: 3.41  Med: 6.43 Max: 11.26
Current: 7.91
3.41
11.26
Days Inventory 292.74
XNPT's Days Inventory is ranked lower than
84% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. XNPT: 292.74 )
Ranked among companies with meaningful Days Inventory only.
XNPT' s Days Inventory Range Over the Past 10 Years
Min: 196.85  Med: 237.06 Max: 271.98
Current: 292.74
196.85
271.98
Days Sales Outstanding 57.10
XNPT's Days Sales Outstanding is ranked higher than
57% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. XNPT: 57.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
XNPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.46  Med: 43.11 Max: 96.22
Current: 57.1
4.46
96.22
Days Payable 354.82
XNPT's Days Payable is ranked higher than
91% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. XNPT: 354.82 )
Ranked among companies with meaningful Days Payable only.
XNPT' s Days Payable Range Over the Past 10 Years
Min: 354.82  Med: 446.74 Max: 494.16
Current: 354.82
354.82
494.16

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 24.24
XNPT's Price/Net Current Asset Value is ranked lower than
86% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. XNPT: 24.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
XNPT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.97  Med: 6.00 Max: 32.29
Current: 24.24
1.97
32.29
Price/Tangible Book 12.88
XNPT's Price/Tangible Book is ranked lower than
84% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. XNPT: 12.88 )
Ranked among companies with meaningful Price/Tangible Book only.
XNPT' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.8  Med: 5.19 Max: 17.16
Current: 12.88
1.8
17.16
Price/Median PS Value 0.46
XNPT's Price/Median PS Value is ranked higher than
81% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. XNPT: 0.46 )
Ranked among companies with meaningful Price/Median PS Value only.
XNPT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.95 Max: 6.66
Current: 0.46
0.23
6.66
Earnings Yield (Greenblatt) (%) -33.66
XNPT's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. XNPT: -33.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XNPT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -33.66  Med: 1.95 Max: 4492.4
Current: -33.66
-33.66
4492.4

More Statistics

Revenue(Mil) $41
EPS $ -1.31
Beta3.20
Short Percentage of Float16.78%
52-Week Range $3.35 - 7.86
Shares Outstanding(Mil)63.46

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 115 90
EPS($) -0.06 -0.77
EPS without NRI($) -0.06 -0.77

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RPTP, NAS:ARNA, NAS:BPMC, NAS:XBIT, XKRX:031390, XKRX:049960 » details
Traded in other countries:LMW.Germany,
XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product and each of its product candidates are orally available, patented molecules that address potential markets with clear unmet medical needs. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. With respect to AP, it has decided to terminate further investment in AP as a treatment for spasticity in patients with MS; however, given a previous, successful Phase 2 clinical trial of AP as a potential treatment for spasticity in spinal cord injury patients. XP21279, in the primary analysis of the trial, the improvement with XP21279/carbidopa dosed three times per day was not statistically good than the improvement seen with optimized Sinemet dosed four or five times per day during the double-blind phase of the trial. It has discussed the results of this trial with experts in Parkinson's disease and with regulatory authorities. As a result, it plans to continue development of XP21279 to the extent its resources permit or it enters into collaboration with a third party. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as govern
» More Articles for XNPT

Headlines

Articles On GuruFocus.com
XenoPort Inc. Reports Operating Results (10-Q) Nov 09 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2010 
XenoPort Inc. Reports Operating Results (10-Q) May 10 2010 
Xenoport - A Shaking Ham Hock Feb 07 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2009 
Weekly Top Insider Buys: Alcoa Inc., ABM Industries Inc., Valhi Inc., XenoPort Inc., and Methode Ele Jul 11 2009 
XenoPort Inc. Reports Operating Results (10-Q) May 07 2009 
Weekly Top Insider Buys: Sovereign Bancorp Inc., Jefferies Group Inc., XenoPort Inc., Sandridge Ener May 24 2008 

More From Other Websites
Edited Transcript of XNPT earnings conference call or presentation 5-May-16 9:00pm GMT May 05 2016
XenoPort reports 1Q loss May 05 2016
XenoPort reports 1Q loss May 05 2016
XENOPORT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 05 2016
4:32 pm Xenoport misses by $0.01, reports revs in-line May 05 2016
XenoPort Reports First Quarter Financial Results May 05 2016
XenoPort Reports First Quarter Financial Results May 05 2016
Q1 2016 Xenoport Inc Earnings Release - After Market Close May 05 2016
XenoPort to Release First Quarter Financial Results on May 5, 2016 Apr 26 2016
XenoPort to Release First Quarter Financial Results on May 5, 2016 Apr 26 2016
XENOPORT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Apr 11 2016
XENOPORT INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 01 2016
XENOPORT INC Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 28 2016
Dr Reddy's Collaborates with XenoPort for Psoriasis Drug Mar 28 2016
Dr. Reddy's Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
#StopMakingExcuses Awareness Campaign for Restless Legs Syndrome Launches During Sleep Awareness... Mar 07 2016
XENOPORT INC Financials Mar 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK